Safe Step Act
Treat and Reduce Obesity Act
Prior Authorization Reform
Workforce Issues
Conrad 30 Program
Support increased research funding for digestive disease research funding in NIH, VA and DoD.
Report language submitted to support increased screening tools for esophageal cancer.
Improving Seniors Timely Access to Care Act, legislation that would reform prior authorization in Medicare Advantage
Medicare physician payment reform
Treat and Reduce Obesity Act, legislation that would cover anti-obesity medications, nutrition counseling and other services under Medicare.
Duration: January 1, 2008
to
present
General Issues: Health Issues , Medical/Disease Research/Clinical Labs , Medicare/Medicaid
Spending: about $5,120,000 (But it's complicated. Here's why.)
It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.
Agencies lobbied since 2008: U.S. Senate, House of Representatives, Natl Institutes of Health (NIH), Centers For Medicare and Medicaid Services (CMS), Centers For Medicare and Medicaid Services (CMS)
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
1st Quarter, 2024
In Q1, American Gastroenterological Association had in-house lobbyists. The report was filed on May 7.
Original Filing: 301578318.xml
Lobbying Issues
Safe Step Act
Treat and Reduce Obesity Act
Prior Authorization Reform
Workforce Issues
Conrad 30 Program
Agencies Lobbied
U.S. Senate
Lobbying Issues
Support increased research funding for digestive disease research funding in NIH, VA and DoD.
Report language submitted to support increased screening tools for esophageal cancer.
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
Improving Seniors Timely Access to Care Act, legislation that would reform prior authorization in Medicare Advantage
Medicare physician payment reform
Treat and Reduce Obesity Act, legislation that would cover anti-obesity medications, nutrition counseling and other services under Medicare.
Agencies Lobbied
U.S. Senate
4th Quarter, 2023
In Q4, American Gastroenterological Association had in-house lobbyists. The report was filed on Jan. 5.
Original Filing: 301521972.xml
Lobbying Issues
Safe Step Act
Treat and Reduce Obesity Act
Prior Authorization Reform
Workforce Issues
Conrad 30 Program
Agencies Lobbied
U.S. Senate
Lobbying Issues
Support increased research funding for digestive disease research funding in NIH, VA and DoD.
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
Improving Seniors Timely Access to Care Act, legislation that would reform prior authorization in Medicare Advantage
Medicare physician payment reform
Treat and Reduce Obesity Act, legislation that would cover anti-obesity medications, nutrition counseling and other services under Medicare.
Agencies Lobbied
U.S. Senate
3rd Quarter, 2023
In Q3, American Gastroenterological Association had in-house lobbyists. The report was filed on Nov. 29, 2023.
Original Filing: 301520044.xml
Lobbying Issues
Safe Step Act
Treat and Reduce Obesity Act
Prior Authorization Reform
Workforce Issues
Conrad 30 Program
Agencies Lobbied
U.S. Senate
Lobbying Issues
Support increased research funding for digestive disease research funding in NIH, VA and DoD.
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
Improving Seniors Timely Access to Care Act, legislation that would reform prior authorization in medicare advantage
Medicare physician payment reform
Agencies Lobbied
U.S. Senate
2nd Quarter, 2023
In Q2, American Gastroenterological Association had in-house lobbyists. The report was filed on Aug. 28, 2023.
Original Filing: 301495522.xml
Lobbying Issues
Safe Step Act
Treat and Reduce Obesity Act
Prior Authorization Reform
Agencies Lobbied
U.S. Senate
Lobbying Issues
Support increased research funding for digestive disease research funding in NIH, VA and DoD.
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
Improving Seniors Timely Access to Care Act, legislation that would reform prior authorization in medicare advantage
Medicare physician payment reform
Agencies Lobbied
U.S. Senate
1st Quarter, 2023
In Q1, American Gastroenterological Association had in-house lobbyists. The report was filed on May 30, 2023.
Original Filing: 301471671.xml
Lobbying Issues
Safe Step Act
Treat and Reduce Obesity Act
Prior Authorization Reform
Agencies Lobbied
U.S. Senate
Lobbying Issues
Support increased research funding for digestive disease research funding in NIH, VA and DoD.
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
Improving Seniors Timely Access to Care Act, legislation that would reform prior authorization in medicare advantage
Medicare physician payment reform
Agencies Lobbied
U.S. Senate
4th Quarter, 2022
In Q4, American Gastroenterological Association had in-house lobbyists. The report was filed on March 8, 2023.
Original Filing: 301447649.xml
Lobbying Issues
Lobbied in support of H.R. 464/H.R. 2163, the Safe Step Act, legislation to provide a fair and transparent appeals process for step therapy protocols.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Lobbied in support of increased federal research funding for the NIH, VA, and DoD's Congressionally Directly Medical Research Program.
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
Lobbied in support of H.R. 3173, the Improving Seniors Timely Access to Care Act, legislation to streamline the prior authorization process in Medicare Advantage.
Lobbied in support of the Treat and Reduce Obesity Act, legislation to provide Medicare coverage of weight-loss counseling, FDA-approved obesity medications, and access and coverage of behavioral counseling.
Lobbied in support of Medicare physician payment relief in 2023.
Agencies Lobbied
U.S. Senate
3rd Quarter, 2022
In Q3, American Gastroenterological Association had in-house lobbyists. The report was filed on Nov. 2, 2022.
Original Filing: 301421765.xml
Lobbying Issues
Lobbied in support of H.R. 464/H.R. 2163, the Safe Step Act, legislation to provide a fair and transparent appeals process for step therapy protocols.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Lobbied in support of increased federal research funding for the NIH, VA, and DoD's Congressionally Directly Medical Research Program.
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
Lobbied in support of H.R. 3173, the Improving Seniors Timely Access to Care Act, legislation to streamline the prior authorization process in Medicare Advantage.
Lobbied in support of the Treat and Reduce Obesity Act, legislation to provide Medicare coverage of weight-loss counseling, FDA-approved obesity medications, and access and coverage of behavioral counseling.
Lobbied in support of Medicare physician payment relief in 2023.
Agencies Lobbied
U.S. Senate
2nd Quarter, 2022
In Q2, American Gastroenterological Association had in-house lobbyists. The report was filed on Aug. 30, 2022.
Original Filing: 301399711.xml
Lobbying Issues
Lobbied in support of H.R. 464/H.R. 2163, the Safe Step Act, legislation to provide a fair and transparent appeals process for step therapy protocols.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Lobbied in support of increased federal research funding for the NIH, VA, and DoD's Congressionally Directly Medical Research Program.
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
Lobbied in support of H.R. 3173, the Improving Seniors Timely Access to Care Act, legislation to streamline the prior authorization process in Medicare Advantage.
Lobbied in support of the Treat and Reduce Obesity Act, legislation to provide Medicare coverage of weight-loss counseling, FDA-approved obesity medications, and access and coverage of behavioral counseling.
Lobbied in support of Medicare physician payment relief in 2023.
Agencies Lobbied
U.S. Senate
1st Quarter, 2022
In Q1, American Gastroenterological Association had in-house lobbyists. The report was filed on April 6, 2022.
Original Filing: 301343917.xml
Lobbying Issues
Lobbied in support of H.R. 464/H.R. 2163, the Safe Step Act, legislation to provide a fair and transparent appeals process for step therapy protocols.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Lobbied in support of increased federal research funding for the NIH, VA, and DoD's Congressionally Directly Medical Research Program.
Lobbied in support of H.R. 289/H.R. 869, the RISE Act, to provide $25 billion in research funding to research facilities whose research was disrupted due to the COVID-19 pandemic.
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
Lobbied in support of H.R. 3173, the Improving Seniors Timely Access to Care Act, legislation to streamline the prior authorization process in Medicare Advantage.
Lobbied in support of the Treat and Reduce Obesity Act, legislation to provide Medicare coverage of weight-loss counseling, FDA-approved obesity medications, and access and coverage of behavioral counseling.
Lobbied in support of Medicare physician payment relief in 2022.
Agencies Lobbied
U.S. Senate
4th Quarter, 2021
In Q4, American Gastroenterological Association had in-house lobbyists. The report was filed on Dec. 21, 2021.
Original Filing: 301319344.xml
Lobbying Issues
Lobbied in support of H.R. 464/H.R. 2163, the Safe Step Act, legislation to provide a fair and transparent appeals process for step therapy protocols.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Lobbied in support of increased federal research funding for the NIH, VA, and DoD's Congressionally Directly Medical Research Program.
Lobbied in support of H.R. 289/H.R. 869, the RISE Act, to provide $25 billion in research funding to research facilities whose research was disrupted due to the COVID-19 pandemic.
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
Lobbied in support of H.R. 3173, the Improving Seniors Timely Access to Care Act, legislation to streamline the prior authorization process in Medicare Advantage.
Lobbied in support of the Treat and Reduce Obesity Act, legislation to provide Medicare coverage of weight-loss counseling, FDA-approved obesity medications, and access and coverage of behavioral counseling.
Lobbied in support of Medicare physician payment relief in 2022.
Agencies Lobbied
U.S. Senate
3rd Quarter, 2021
In Q3, American Gastroenterological Association had in-house lobbyists. The report was filed on Nov. 3, 2021.
Original Filing: 301317031.xml
Lobbying Issues
Lobbied in support of H.R. 464/H.R. 2163, the Safe Step Act, legislation to provide a fair and transparent appeals process for step therapy protocols.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Lobbied in support of increased federal research funding for the NIH, VA, and DoD's Congressionally Directly Medical Research Program.
Lobbied in support of H.R. 289/H.R. 869, the RISE Act, to provide $25 billion in research funding to research facilities whose research was disrupted due to the COVID-19 pandemic.
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
Lobbied in support of H.R. 3173, the Improving Seniors Timely Access to Care Act, legislation to streamline the prior authorization process in Medicare Advantage.
Lobbied in support of the Treat and Reduce Obesity Act, legislation to provide Medicare coverage of weight-loss counseling, FDA-approved obesity medications, and access and coverage of behavioral counseling.
Agencies Lobbied
U.S. Senate
2nd Quarter, 2021
In Q2, American Gastroenterological Association had in-house lobbyists. The report was filed on Sept. 24, 2021.
Original Filing: 301295799.xml
Lobbying Issues
Lobbied in support of H.R. 464/H.R. 2163, the Safe Step Act, legislation to provide a fair and transparent appeals process for step therapy protocols.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Lobbied in support of increased federal research funding for the NIH, VA, and DoD's Congressionally Directly Medical Research Program.
Lobbied in support of H.R. 289/H.R. 869, the RISE Act, to provide $25 billion in research funding to research facilities whose research was disrupted due to the COVID-19 pandemic.
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
Lobbied in support of H.R. 3173, the Improving Seniors Timely Access to Care Act, legislation to streamline the prior authorization process in Medicare Advantage.
Lobbied in support of the Treat and Reduce Obesity Act, legislation to provide Medicare coverage of weight-loss counseling, FDA-approved obesity medications, and access and coverage of behavioral counseling.
Agencies Lobbied
U.S. Senate
1st Quarter, 2021
In Q1, American Gastroenterological Association had in-house lobbyists. The report was filed on May 26, 2021.
Original Filing: 301271629.xml
Lobbying Issues
Lobbied in support of H.R. 464/H.R. 2163, the Safe Step Act, legislation to provide a fair and transparent appeals process for step therapy protocols.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Lobbied in support of increased federal research funding for the NIH, VA, and DoD's Congressionally Directly Medical Research Program.
Lobbied in support of H.R. 289/H.R. 869, the RISE Act, to provide $25 billion in research funding to research facilities whose research was disrupted due to the COVID-19 pandemic.
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
Lobbied in support of H.R. 3173, the Improving Seniors Timely Access to Care Act, legislation to streamline the prior authorization process in Medicare Advantage.
Lobbied in support of the Treat and Reduce Obesity Act, legislation to provide Medicare coverage of weight-loss counseling, FDA-approved obesity medications, and access and coverage of behavioral counseling.
Agencies Lobbied
U.S. Senate
4th Quarter, 2020
In Q4, American Gastroenterological Association had in-house lobbyists. The report was filed on Jan. 8, 2021.
Original Filing: 301229414.xml
Lobbying Issues
Safe Step Act HR 2279/S. 2546
Telehealth Expansion HR 6644
COVID Relief for Physicians: HR 6720, HR 7059, HR 2895/S. 948, HR 6788/S. 3599, HR 7077/S. 3877
Agencies Lobbied
U.S. Senate
Lobbying Issues
Lobbied in support of increased federal funding of digestive disease research at the NIH, VA and DoD.
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
HR 3107, the Improving Seniors Timely Access to Care Act
HR 1570/S. 688 Removing Barriers to Colorectal Cancer Screening ACt
Agencies Lobbied
U.S. Senate
3rd Quarter, 2020
In Q3, American Gastroenterological Association had in-house lobbyists. The report was filed on Nov. 17, 2020.
Original Filing: 301226775.xml
Lobbying Issues
Safe Step Act HR 2279/S. 2546
Telehealth Expansion HR 6644
COVID Relief for Physicians: HR 6720, HR 7059, HR 2895/S. 948, HR 6788/S. 3599, HR 7077/S. 3877
Agencies Lobbied
U.S. Senate
Lobbying Issues
Lobbied in support of increased federal funding of digestive disease research at the NIH, VA and DoD.
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
HR 3107, the Improving Seniors Timely Access to Care Act
HR 1570/S. 688 Removing Barriers to Colorectal Cancer Screening ACt
Agencies Lobbied
U.S. Senate
1st Quarter, 2020
In Q1, American Gastroenterological Association had in-house lobbyists. The report was filed on May 22, 2020.
Original Filing: 301183413.xml
Lobbying Issues
Lobbied in support of HR 2279, the Safe Step Act, legislation that will provide a clear and transparent appeals process for physicians to appeal a step therapy protocol on behalf of their patients.
Lobbied in support of S. 2546, Safe Step Act.
Lobbied in support of legislation to address surprise billing, specifically that provide an independent dispute resolution for physicians.
Lobbied in support of federal assistance for physicians and physician practices impacted by the pandemic.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Lobbied for a $2 billion increase in funding for the NIH. Also lobbied for increased funding for the VA's medical and prosthetic research program as well as increased funding for the DoD's Peer-Reviewed Cancer Research Program.
Also lobbied in support of report language to the FY2021 Labor-HHS Appropriations bill to support funding for the FMT Registry.
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
Lobbied in support of H.R. 1570 Removing Barriers to Colorectal Cancer Screening Act, legislation that would waive the coinsurance for Medicare beneficiaries when their screening colonoscopy becomes therapeutic.
Lobbied in support of H.R. 3107, Seniors Timely Access to Care Act, legislation that would streamline the prior authorization process in the Medicare Advantage program.
Agencies Lobbied
U.S. Senate
4th Quarter, 2019
In Q4, American Gastroenterological Association had in-house lobbyists. The report was filed on Feb. 13, 2020.
Original Filing: 301131759.xml
Lobbying Issues
Lobbied in support of HR 2279, the Safe Step Act, legislation that will provide a clear and transparent appeals process for physicians to appeal a step therapy protocol on behalf of their patients.
Lobbied in support of S. 2546, Safe Step Act.
Lobbied in support of legislation to address surprise billing, specifically that provide an independent dispute resolution for physicians.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Lobbied for a $2 billion increase in funding for the NIH. Also lobbied for increased funding for the VA's medical and prosthetic research program as well as increased funding for the DoD's Peer-Reviewed Cancer Research Program.
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
Lobbied in support of H.R. 1570 Removing Barriers to Colorectal Cancer Screening Act, legislation that would waive the coinsurance for Medicare beneficiaries when their screening colonoscopy becomes therapeutic.
Lobbied in support of H.R. 3107, Seniors Timely Access to Care Act, legislation that would streamline the prior authorization process in the Medicare Advantage program.
Agencies Lobbied
U.S. Senate
3rd Quarter, 2019
In Q3, American Gastroenterological Association had in-house lobbyists. The report was filed on Oct. 16, 2019.
Original Filing: 301066692.xml
Lobbying Issues
Lobbied in support of HR 2279, the Safe Step Act, legislation that will provide a clear and transparent appeals process for physicians to appeal a step therapy protocol on behalf of their patients.
Lobbied in support of legislation to address surprise billing.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Lobbied for a $2 billion increase in funding for the NIH. Also lobbied for increased funding for the VA's medical and prosthetic research program as well as increased funding for the DoD's Peer-Reviewed Cancer Research Program.
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
Lobbied in support of H.R. 1570 Removing Barriers to Colorectal Cancer Screening Act, legislation that would waive the coinsurance for Medicare beneficiaries when their screening colonoscopy becomes therapeutic.
Lobbied in support of H.R. 3107, Seniors Timely Access to Care Act, legislation that would streamline the prior authorization process in the Medicare Advantage program.
Agencies Lobbied
U.S. Senate
2nd Quarter, 2019
In Q2, American Gastroenterological Association had in-house lobbyists. The report was filed on July 8, 2019.
Original Filing: 301043445.xml
Lobbying Issues
Lobbied in support of HR 2279, the Safe Step Act, legislation that will provide a clear and transparent appeals process for physicians to appeal a step therapy protocol on behalf of their patients.
Lobbied in support of legislation to address patent abuses by the pharmaceutical industry that delay the development of generics reaching the market (CREATES Act).
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Lobbied for a $2 billion increase in funding for the NIH. Also lobbied for increased funding for the VA's medical and prosthetic research program as well as increased funding for the DoD's Peer-Reviewed Cancer Research Program.
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
Lobbied in support of H.R. 1570 Removing Barriers to Colorectal Cancer Screening Act, legislation that would waive the coinsurance for Medicare beneficiaries when their screening colonoscopy becomes therapeutic.
Lobbied in support of H.R. 3107, Seniors Timely Access to Care Act, legislation that would streamline the prior authorization process in the Medicare Advantage program.
Agencies Lobbied
U.S. Senate
1st Quarter, 2019
In Q1, American Gastroenterological Association had in-house lobbyists. The report was filed on May 24, 2019.
Original Filing: 301041526.xml
Lobbying Issues
Lobbied in support of HR 2279, the Safe Step Act, legislation that will provide a clear and transparent appeals process for physicians to appeal a step therapy protocol on behalf of their patients.
Lobbied in support of legislation to address patent abuses by the pharmaceutical industry that delay the development of generics reaching the market (CREATES Act).
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Lobbied for a $2 billion increase in funding for the NIH. Also lobbied for increased funding for the VA's medical and prosthetic research program as well as increased funding for the DoD's Peer-Reviewed Cancer Research Program.
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
Lobbied in support of the Removing Barriers to Colorectal Cancer Screening Act, legislation that would waive the coinsurance for Medicare beneficiaries when their screening colonoscopy becomes therapeutic.
Agencies Lobbied
U.S. Senate
4th Quarter, 2018
In Q4, American Gastroenterological Association had in-house lobbyists. The report was filed on Jan. 16, 2019.
Original Filing: 301005578.xml
Lobbying Issues
Lobbied in support of HR 2077, the Restoring Patient's Voice Act
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Lobbied in support of increased funding for the NIH, NIDDK, NCI and federal research funding for DoD and the VA.
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
Lobbied in support of HR 1017/S.479, the Removing Barriers to Colorectal Cancer Screening Act. Also lobbied for a more streamlined prior authorization process in Medicare Advantage plans.
Agencies Lobbied
U.S. Senate
3rd Quarter, 2018
In Q3, American Gastroenterological Association had in-house lobbyists. The report was filed on Oct. 1, 2018.
Original Filing: 300982199.xml
Lobbying Issues
Lobbied in support of HR 2077, the Restoring Patient's Voice Act
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Lobbied in support of increased funding for the NIH, NIDDK, NCI and federal research funding for DoD and the VA.
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
Lobbied in support of HR 1017/S.479, the Removing Barriers to Colorectal Cancer Screening Act. Also lobbied for a more streamlined prior authorization process in Medicare Advantage plans.
Agencies Lobbied
U.S. Senate
2nd Quarter, 2018
In Q2, American Gastroenterological Association had in-house lobbyists. The report was filed on July 11, 2018.
Original Filing: 300963571.xml
Lobbying Issues
Lobbied in support of HR 2077, the Restoring Patient's Voice Act
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Lobbied in support of increased funding for the NIH, NIDDK, NCI and federal research funding for DoD and the VA.
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
Lobbied in support of HR 1017/S.479, the Removing Barriers to Colorectal Cancer Screening Act. Also advocated for changes to the MACRA law to provide CMS more flexibility when implementing MIPS in both the cost and performance categories.
Agencies Lobbied
U.S. Senate
1st Quarter, 2018
In Q1, American Gastroenterological Association had in-house lobbyists. The report was filed on May 30, 2018.
Original Filing: 300960795.xml
Lobbying Issues
Lobbied in support of HR 2077, the Restoring Patient's Voice Act
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Lobbied in support of increased funding for the NIH, NIDDK, NCI and federal research funding for DoD and the VA.
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
Lobbied in support of HR 1017/S.479, the Removing Barriers to Colorectal Cancer Screening Act. Also advocated for changes to the MACRA law to provide CMS more flexibility when implementing MIPS in both the cost and performance categories.
Agencies Lobbied
U.S. Senate
4th Quarter, 2017
In Q4, American Gastroenterological Association had in-house lobbyists. The report was filed on Jan. 30, 2018.
Original Filing: 300939108.xml
Lobbying Issues
Lobbied in support of HR 2077, the Restoring Patient's Voice Act
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Lobbied in support of increased funding for the NIH, NIDDK, NCI and federal research funding for DoD and the VA.
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
Lobbied in support of HR 1017/S.479, the Removing Barriers to Colorectal Cancer Screening Act. Also advocated for changes to the MACRA law to provide CMS more flexibility when implementing MIPS in both the cost and performance categories.
Agencies Lobbied
U.S. Senate
3rd Quarter, 2017
In Q3, American Gastroenterological Association had in-house lobbyists. The report was filed on Jan. 30, 2018.
Original Filing: 300939111.xml
Lobbying Issues
Lobbied in support of HR 1071, the Removing Barriers to CRC Screening Act, that would waive the cost sharing for a screening colonoscopy under Medicare regardless of the outcome.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Lobbied in support of increased research funding for NIH, NCI, NIDDK, DoD and VA medical research programs.
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
Lobbied in support of retaining the essential health benefits package in the ACA along with other patient protections.
Agencies Lobbied
U.S. Senate
2nd Quarter, 2017
In Q2, American Gastroenterological Association had in-house lobbyists. The report was filed on Dec. 19, 2017.
Original Filing: 300920491.xml
Lobbying Issues
Lobbied in support of HR 1071, the Removing Barriers to CRC Screening Act, that would waive the cost sharing for a screening colonoscopy under Medicare regardless of the outcome.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Lobbied in support of increased research funding for NIH, NCI, NIDDK, DoD and VA medical research programs.
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
Lobbied in support of retaining the essential health benefits package in the ACA along with other patient protections.
Agencies Lobbied
U.S. Senate
1st Quarter, 2017
In Q1, American Gastroenterological Association had in-house lobbyists. The report was filed on June 5, 2017.
Original Filing: 300880863.xml
Lobbying Issues
Lobbied in support of HR 1071, the Removing Barriers to CRC Screening Act, that would waive the cost sharing for a screening colonoscopy under Medicare regardless of the outcome.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Lobbied in support of increased research funding for NIH, NCI, NIDDK, DoD and VA medical research programs.
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
Lobbied in support of retaining the essential health benefits package in the ACA along with other patient protections.
Agencies Lobbied
U.S. Senate
4th Quarter, 2016
In Q4, American Gastroenterological Association had in-house lobbyists. The report was filed on Jan. 25, 2017.
Original Filing: 300859086.xml
Lobbying Issues
Lobbied in support of H.R. 1220/S. 624, the Removing Barriers to Colorectal Cancer Screening Act. Also lobbied in favor of specialists being able to qualify as alternative payment models under MACRA.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Lobbied in support of funding for digestive disease research at NIH, VA and DoD.
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
Lobbied in support of the 21st Century Cures Act
Agencies Lobbied
U.S. Senate
3rd Quarter, 2016
In Q3, American Gastroenterological Association had in-house lobbyists. The report was filed on Oct. 6, 2016.
Original Filing: 300825631.xml
Lobbying Issues
Lobbied in support of H.R. 1220/S. 624, the Removing Barriers to Colorectal Cancer Screening Act. Also lobbied in favor of specialists being able to qualify as alternative payment models under MACRA.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Lobbied in support of funding for digestive disease research at NIH, VA and DoD.
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
2nd Quarter, 2016
In Q2, American Gastroenterological Association had in-house lobbyists. The report was filed on Jan. 25, 2017.
Original Filing: 300859085.xml
Lobbying Issues
Lobbied in support of the Electronic Health Record Improvement Act, legislation that would exempt patient encounters performed in an ASC from being counted toward a physician's meaningful use requirement.
Lobbied in support of the 21st Century Cures Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Lobbied in support of H.R. 1220/S. 624, the Removing Barriers to Colorectal Cancer Screening Act, legislation that would waive the coinsurance for a screening colonoscopy regardless of the outcome of the screening. Lobbied in support of specialists being able to qualify as alternative payment models under MACRA.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Lobbied in support of funding increases for the NIH, NIDDK, VA Research Programs and DoD Research Programs.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Medical/Disease Research/Clinical Labs
1st Quarter, 2016
In Q1, American Gastroenterological Association had in-house lobbyists. The report was filed on Oct. 6, 2016.
Original Filing: 300825625.xml
Lobbying Issues
Lobbied in support of S. 1347, Electronic Health Record Improvement Act, legislation that would exempt patient encounters performed in an ASC from being counted toward a physician's meaningful use requirement.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Lobbied in support of H.R. 1220/S. 624, the Removing Barriers to Colorectal Cancer Screening Act, legislation that would waive the coinsurance for a screening colonoscopy regardless of the outcome of the screening. Lobbied in support of specialists being able to qualify as alternative payment models under MACRA.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Lobbied in support of funding increases for the NIH, NIDDK, VA Research Programs and DoD Research Programs.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Medical/Disease Research/Clinical Labs
4th Quarter, 2015
In Q4, American Gastroenterological Association had in-house lobbyists. The report was filed on Jan. 20, 2016.
Original Filing: 300779278.xml
Lobbying Issues
Lobbied in support of S. 1347, Electronic Health Record Improvement Act, legislation that would exempt patient encounters performed in an ASC from being counted toward a physician's meaningful use requirement.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Lobbied in support of H.R. 1220/S. 624, the Removing Barriers to Colorectal Cancer Screening Act, legislation that would waive the coinsurance for a screening colonoscopy regardless of the outcome of the screening.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Lobbied in support of funding increases for the NIH, NIDDK, VA Research Programs and DoD Research Programs.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Medical/Disease Research/Clinical Labs
3rd Quarter, 2015
In Q3, American Gastroenterological Association had in-house lobbyists. The report was filed on Jan. 20, 2016.
Original Filing: 300779332.xml
Lobbying Issues
Lobbied in support of HR 1220/S 624, Removing Barriers to Colorectal Cancer Screening Act, legislation that would waive the coinsurance for Medicare screening colonoscopy regardless of the outcome of the screening.
Lobbied in support of repealing the Sustainable Growth Rate used to calculate physician payments under Medicare.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Lobbied in support of the 21st Century Cures Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Lobbied in support of increased funding for NIH and NIDDK.
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
2nd Quarter, 2015
In Q2, American Gastroenterological Association lobbied for AMERICAN GASTROENTEROLOGICAL ASSN , earning $80,000. The report was filed on July 16, 2015.
Original Filing: 300736368.xml
Lobbying Issues
Lobbied in support of repeal the sustainable growth rate formula used to calculate Medicare physician payment rates.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Lobbied in support of the 21st Century Cures Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Lobbied in support of increased funding for NIH and NIDDK.
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
1st Quarter, 2015
In Q1, American Gastroenterological Association lobbied for AMERICAN GASTROENTEROLOGICAL ASSN , earning $80,000. The report was filed on Aug. 24, 2015.
Original Filing: 300749362.xml
Lobbying Issues
Lobbied in support of repealing the sustainable growth rate formula used to calculate Medicare physician payment rates.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Lobbied in support of 21st Century Cures Act
Agencies Lobbied
U.S. Senate
Lobbying Issues
Lobbied in support of increased research funding for NIH, NIDDK, VA and DoD Cancer Research programs.
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
4th Quarter, 2014
In Q4, American Gastroenterological Association had in-house lobbyists. The report was filed on June 5, 2017.
Original Filing: 300880864.xml
Lobbying Issues
Lobbied in support of the Removing Barriers to CRC Screening Act to waive the cost sharing for a screening colonoscopy regardless of the outcome. Also lobbied in support of more transparency at CMS when changing values of physician payments.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Lobbied in support of 21st Century Cures Act and improvement in HIT interoperability.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Lobbied in support of increased research funding for NIH, NCI, NIDDK, VA and DoD medical research programs.
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
3rd Quarter, 2014
In Q3, AMERICAN GASTROENTEROLOGICAL ASSN had in-house lobbyists. The report was filed on Nov. 4, 2014.
Original Filing: 300690837.xml
Lobbying Issues
Lobbied in support of the Removing Barriers to Screening Act, legislation to waive the screening colonoscopy coinsurance when the screening turns therapeutic. Also lobbied in support of a more transparent process at CMS for announcing changes in physician values.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Lobbied in support of increased funding for digestive disease research at NIH, NIDDK, VA and DoD.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Medical/Disease Research/Clinical Labs
2nd Quarter, 2014
In Q2, AMERICAN GASTROENTEROLOGICAL ASSN had in-house lobbyists. The report was filed on Aug. 27, 2014.
Original Filing: 300672505.xml
Lobbying Issues
Lobbied for support of the Eliminating Barriers to Colorectal Cancer Screening Act, legislation that would waive the coinsurance for Medicare beneficiaries whose screening colonoscopy becomes therapeutic. Also lobbied in support of a more open and transparent process when CMS makes changes to physician payment values.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Lobbied in support of increased funding for biomedical research at the NIH, VA and DoD.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Medical/Disease Research/Clinical Labs
1st Quarter, 2014
In Q1, AMERICAN GASTROENTEROLOGICAL ASSN had in-house lobbyists. The report was filed on May 15, 2014.
Original Filing: 300651697.xml
Lobbying Issues
Lobbied in support of a permanent fix to the SGR Medicare Physician Payment formula. Lobbied in support of more transparency at CMS when publishing changes in physician values. Lobbied in support of H.R. 1070, Removing Barriers to Colorectal Cancer Screening Act. Lobbied in support of repealing IPAB.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Lobbied in support of increased research funding for the NIH, VA and DoD Cancer Reserach programs.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Medical/Disease Research/Clinical Labs
4th Quarter, 2013
In Q4, AMERICAN GASTROENTEROLOGICAL ASSN had in-house lobbyists. The report was filed on Jan. 8, 2014.
Original Filing: 300611966.xml
Lobbying Issues
Lobbied in support of a permanent fix to the SGR and meaningful physician payment reform. Lobbied in support of H.R. 1070, the Removing Barriers to Colorectal Cancer Screenings Act. Lobbied in support of the repeal of the Independent Payment Advisory Board (IPAB). Lobbied to maintain the current in-office ancillary services exception under Medicare.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Lobbied in support of federal funding of biomedical research and funding for the National Institutes of Health (NIH) and the Veterans Administration's research program.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Medical/Disease Research/Clinical Labs
3rd Quarter, 2013
In Q3, AMERICAN GASTROENTEROLOGICAL ASSN had in-house lobbyists. The report was filed on Nov. 12, 2013.
Original Filing: 300609715.xml
Lobbying Issues
Lobbied in support of a permanent fix to the SGR and meaningful physician payment reform. Lobbied in support of H.R. 1070, the Removing Barriers to Colorectal Cancer Screening act. Lobbied in support of repeal of the Independent Payment Advisory Board (IPAB). Lobbied to maintain the current in-office ancillary services exception under Medicare.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Lobbied in support of federal funding of biomedical research and funding for the National Institutes of Health (NIH) and the Veterans Administration's research program.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Medical/Disease Research/Clinical Labs
2nd Quarter, 2013
In Q2, AMERICAN GASTROENTEROLOGICAL ASSN had in-house lobbyists. The report was filed on Aug. 14, 2013.
Original Filing: 300589037.xml
Lobbying Issues
Advocated for a new Medicare physician payment system and a repeal of the SGR formula used to calculate Medicare payments. Also advocated in support of the Eliminating Barriers to Colorectal Cancer Screening which would waive the co-insurance for Medicare beneficiaries who undergo a screening colonoscopy that turns therapeutic.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Lobbied in support of H.R. 5, the HEALTH Act, and other measures to reform medical liability. Also, advocated for legislation to repeal the Independent Payment Advisory Board (IPAB).
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Lobbied in support of increased federal funding of biomedical research through the VA, NIH, NIDDK and DoD.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Medical/Disease Research/Clinical Labs
1st Quarter, 2013
In Q1, AMERICAN GASTROENTEROLOGICAL ASSN had in-house lobbyists. The report was filed on April 9, 2013.
Original Filing: 300548026.xml
Lobbying Issues
Lobbied in support of H.R. 1070, the Removing Barriers to Colorectal Cancer Screening Act. Lobbied in support of Medicare physician payment reform. Lobbied in support of repeal the Independent Payment Advisory Board (IPAB).
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Lobbied in support of federal funding of biomedical research and funding for the National Institutes of Health (NIH).
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Medical/Disease Research/Clinical Labs
4th Quarter, 2012
In Q4, AMERICAN GASTROENTEROLOGICAL ASSN had in-house lobbyists. The report was filed on Jan. 29, 2013.
Original Filing: 300544109.xml
Lobbying Issues
Lobbied for a permanent fix to the Medicare physician payment system and prevent the scheduled 26.5 percent cut from being implemeted. Lobbied to include registry recognition language in a year end SGR fix bill. Lobbied in support of HR 4120, Removing Barriers to Colorectal Cancer Screening Act.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Lobbied to prevent the automatic spending cuts to the National Institutes of Health (NIH) and urged funding of $32 billion for NIH for fiscal year 2013.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Medical/Disease Research/Clinical Labs
3rd Quarter, 2012
In Q3, AMERICAN GASTROENTEROLOGICAL ASSN had in-house lobbyists. The report was filed on Oct. 23, 2012.
Original Filing: 300521819.xml
Lobbying Issues
Lobbied in support of H.R. 4120, Removing Barriers to Colorectal Cancer Screening Act. Lobbied to prevent a 27 percent cut to Medicare physician payments. Lobbied to delay the implementation of the value based payment modifier under Medicare.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Lobbied in support of H.R. 733, the Pancreatic Cancer Research and Education Act. Lobbied in support of medical research funding for the NIH, VA and DoD.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Medical/Disease Research/Clinical Labs
2nd Quarter, 2012
In Q2, AMERICAN GASTROENTEROLOGICAL ASSN had in-house lobbyists. The report was filed on Aug. 24, 2012.
Original Filing: 300502127.xml
Lobbying Issues
Lobbied in support of increased funding for disgestive disease research at the NIH, NIDDK, VA and DoD.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Lobbied in support of medical liability reform and in support of HR 5.
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2012
In Q1, AMERICAN GASTROENTEROLOGICAL ASSN had in-house lobbyists. The report was filed on April 20, 2012.
Original Filing: 300472848.xml
Lobbying Issues
Lobbied in support of H.R. 4120, the Eliminate Barriers to Colorectal Cancer. Advocated for a repeal of the sustainable growth rate formula (SGR) that determines Medicare physician payments. Lobbied in support of H.R. 452, the Medicare Decisions Accountability Act.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
Advocated in support of H.R. 5, the HEALTH Act, that would provide federal medical liability reform. Advocated in support of PDUFA and advocated that Congress address the drug shortage in the user fee authorization bill.
Agencies Lobbied
U.S. House of Representatives
4th Quarter, 2011
In Q4, AMERICAN GASTROENTEROLOGICAL ASSN had in-house lobbyists. The report was filed on Jan. 18, 2012.
Original Filing: 300441567.xml
Lobbying Issues
Advocated for a technical correction to the Medicare screening colonoscopy coinsurance waiver to ensure that the coinsurance is waived when the screening becomes therapeutic. Advocated for a repeal of the SGR formula used to determine Medicare physician payment updates. Also advocated for the repeal of the Independent Payment Advisory Board and in support of the ASC Access and Quality Act.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Advocated for increased medical research funding for the NIH, NIDDK and the VA to support digestive disease research.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Medical/Disease Research/Clinical Labs
3rd Quarter, 2011
In Q3, AMERICAN GASTROENTEROLOGICAL ASSN had in-house lobbyists. The report was filed on Oct. 19, 2011.
Original Filing: 300420597.xml
Lobbying Issues
Advocated in support of H.R. 5, the HEALTH Act, that would provide federal medical liability reform.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Advocated for increased medical research funding for the NIH, NIDDK, and VA.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
Advocated for a technical correction to the Medicare colorectal cancer coinsurance waiver to ensure that the coinsurance is waived for a screening colonoscopy that becomes therapeutic. Advocated for repeal of the sustainable growth rate formula (SGR) and that Congress prevent a 30 percent reduction in physician reimbursement for Medicare services. Also advocated for the repeal of the Independent Payment Advisory Board (IPAB) and in support of the ASC Access and Quality Act.
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2011
In Q2, AMERICAN GASTROENTEROLOGICAL ASSN had in-house lobbyists. The report was filed on July 25, 2011.
Original Filing: 300406969.xml
Lobbying Issues
Lobbied for a permanent fix to the Medicare physician payment formula. Lobbied for a waiver of the copayment for colorectal cancer screenings under Medicare when the colonoscopy becomes therapeutic. Lobbied in favor of repeal of the Independent Payment Advisory Board (IPAB).
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Lobbied for increased federal funding for medical research for the NIH, NIDDK, VA and DOD. Also lobbied for the implementation of the recommendations of the National Commission on Digestive Diseases.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
Lobbied in support of H.R. 5, the HEALTH Act, that would reform medical liability. Also lobbied in support of the Colorectal Cancer Early Detection, Prevention and Treatment Act.
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2011
In Q1, AMERICAN GASTROENTEROLOGICAL ASSN had in-house lobbyists. The report was filed on April 21, 2011.
Original Filing: 300380849.xml
Lobbying Issues
Lobbied for a permanent fix to the Medicare physician payment formula; advocated for the repeal of the Independent Payment Advisory Board; advocated for the waiver of the copayment for Medicare colorectal cancer screening for therapeutic colonoscopy.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Advocated for increased funding for digestive disease research at hte NIH, NIDDK, and the VA and lobbied against cuts to research in H.R. 1.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Medical/Disease Research/Clinical Labs
4th Quarter, 2010
In Q4, AMERICAN GASTROENTEROLOGICAL ASSN had in-house lobbyists. The report was filed on Jan. 24, 2011.
Original Filing: 300355871.xml
Lobbying Issues
Lobbied for a permanent fix to the Medicare physician payment formula and to prevent a 25 percent cut in physician reimbursement. Also lobbied for a technical correction to the Medicare colorectal cancer screening waiver of copayment for a screening colonoscopy that becomes therapeutic.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Lobbied for increased research funding for digestive disease research at NIH and the VA. Also lobbied for support and passage of H.Res. 1444 which commemorates the 60th anniversary of the NIDDK.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Medical/Disease Research/Clinical Labs
3rd Quarter, 2010
In Q3, AMERICAN GASTROENTEROLOGICAL ASSN had in-house lobbyists. The report was filed on Nov. 1, 2010.
Original Filing: 300331871.xml
Lobbying Issues
Lobbied for a permanent fix to the Medicare physician payment formula and to prevent a 23 percent cut in physician reimbursement scheduled for Dec. 1, 2010. Also lobbied for the elimination of the Independent Payment Advisory Board under PPACA which would make funding recommendations on Medicare. Also lobbied for a technical correction to the screening provisions under PPACA for Medicare beneficiaries that the co-payment be waived for a screening colonoscopy that becomes therapeutic.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Lobbied for increased funding for federal funding of digestive disease research at the NIH, NIDDK and VA. Also advocated in support of H.Res. 1444 which commemorates the 60th anniversary of the NIDDK.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Medical/Disease Research/Clinical Labs
2nd Quarter, 2010
In Q2, AMERICAN GASTROENTEROLOGICAL ASSN had in-house lobbyists. The report was filed on July 19, 2010.
Original Filing: 300293446.xml
Lobbying Issues
Lobbied for a permanent fix to the Medicare physician payment formula and to prevent a 21.3 percent cut in physician payments under Medicare from being implemented.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Advocated for increased funding for digestive disease research at the NIH, NIDDK, and the VA. Also advocated for the implementation of the recommendations of the National Commission on Digestive Diseases. Also lobbied in support of a resolution, H.Res. 1444, to commemorate the 60th anniversary of NIDDK.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
Advocated for health care reform and issues concerning expanding access to colorectal cancer screenings, comparative effectiveness research, access to specialty care and opposition to the Independent Payment Advisory Board.
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2010
In Q1, AMERICAN GASTROENTEROLOGICAL ASSN had in-house lobbyists. The report was filed on April 28, 2010.
Original Filing: 300277765.xml
Lobbying Issues
Lobbied for a permanent fix to the Medicare physician payment formula and to prevent a 21% cut in physician reimbursement. Also lobbied for a one-year delay in the implementation of the elimination of consultation codes implemented by CMS.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Advocated for increased funding for digestive disease research at the NIH, NIDDK and the VA. Also advocated for implementation of the recommendations of the National Commission on Digestive Diseases.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
Advocated for health care reform and issues concerning expanding access to colorectal cancer screenings, comparative effectiveness research, access to specialty care and opposition to an Independent Payment Advisory Board. Also advocated in support of increased funding for the CDC's Colorectal Cancer Screening Program.
Agencies Lobbied
U.S. House of Representatives
4th Quarter, 2009
In Q4, AMERICAN GASTROENTEROLOGICAL ASSN had in-house lobbyists. The report was filed on Jan. 11, 2010.
Original Filing: 300228930.xml
Lobbying Issues
Lobbied for a permanent fix to the Medicare Physician Payment formula and to prevent a 21% cut from being implemented in January 2010. Also lobbied in support of HR 3961, the Medicare Physician Payment Reform Act. Also lobbied in support of a technical correction to the Medicare colorectal cancer screening deductible to ensure the deductible is waived regardless if a polyp or lesion is found. Also lobbied for a one-year delay in the elimination of consultation codes by CMS.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Advocate for increased funding for digestive disease research at the NIH, NIDDK, and the VA. Also advocated for the implementation of the recommendations of the National Commission on Digestive Diseases. Also lobbied for report language to support an Institute of Medicine study to examine the plight of the MD/PhD investigator and issues involved with the recruitment and retention of physician scientists.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
Advocated for health care reform and issues concerning expanding access to colorectal cancer screening, comparative effectiveness research, health information technology, access to specialty care and graduate medical education.
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2009
In Q3, AMERICAN GASTROENTEROLOGICAL ASSN had in-house lobbyists. The report was filed on Oct. 16, 2009.
Original Filing: 300207656.xml
Lobbying Issues
Lobbied for a permanent fix to the Medicare physician payment formula and to prevent a 21% cut from being implemented in January 2010. Also lobbied for a technical correction to the Medicare colorectal cancer screening deductible waiver to allow the waiver regardless if a polyp or lesion is found. Also lobbied to secure access to medical specialists.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Advocate for increased funding for digestive disease research at the NIH, NIDDK and the VA. Also advocated for the implementation of the recommendations of the National Commission on Digestive Diseases. Also lobbied for report language to support an Institute of Medicine study to examine the plight of the MD/PhD investigator and issues involved with recruitment and retention of physician-scientists.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
Advocated for health care reform and issues concerning comparative effectiveness research, health information technology, access to specialty care, and graduate medical education. Also advocated for increased access and coverage of colorectal cancer screenings for the uninsured and underinsured.
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2009
In Q2, AMERICAN GASTROENTEROLOGICAL ASSN had in-house lobbyists. The report was filed on July 17, 2009.
Original Filing: 300183041.xml
Lobbying Issues
Lobbied for a permanent fix to the Medicare physician payment formula and to prevent a 21% cut from being implemented in January 2010. Also lobbied for a technical correction to the Medicare colorectal cancer screening deductible waiver to allow the waiver regardless if a polyp or lesion is found. Also lobbied to secure access to medical specialists.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Advocate for increased funding for digestive disease research at he NIH, NIDDK and the VA. Also advocated for implementation of the recommendations of the National Commission on Digestive Diseases. Also lobbied for report language to support an Institute of Medicine study to examine the plight of the MD/PhD investigator and issues involved with recruitment and retention of physician-scientists.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
Advocated for health care reform and issues concerning comparative effectiveness research, health information technology, access to specialty care, and graduate medical education. Also advocated for increased access to colorectal cancer screenings for the uninsured and underinsured.
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2009
In Q1, AMERICAN GASTROENTEROLOGICAL ASSN had in-house lobbyists. The report was filed on April 17, 2009.
Original Filing: 300154418.xml
Lobbying Issues
Advocate for reforming the current Medicare physician payment system and preventing a 20 percent cut in physician payments. Also lobbied for fair reimbursement for gastroenterologists. Also, lobbied for a technical correction to the current Medicare colorectal cancer deductible waiver for beneficiaries and that it be changed to waive the deductible regardless if a polyp or lesion is found.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Advocate for increased federal funding for digestive disease research at NIH, NIDDK and VA research programs. Advocate for language in the Labor-HHS Appropriations bill to include an Insitute of Medicine study to examine the plight of the MD/PhD investigator and issues involved with recruitment and retention of physician-scientists.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
Lobbied in support of H.R. 1189, the Colorectal Cancer Early Detection, Prevention and Treatment Act, to provide grants to states to develop screening programs for the at-risk, uninsured and underinsured populations. Also, lobbied in support of S. 717, the 21st Century ALERT Act, which would also create a colorectal cancer screening program and increase research programs for high mortality cancers such as esophageal, liver and stomach.
Agencies Lobbied
U.S. House of Representatives
4th Quarter, 2008
In Q4, AMERICAN GASTROENTEROLOGICAL ASSN had in-house lobbyists. The report was filed on Jan. 29, 2009.
Original Filing: 300135766.xml
Lobbying Issues
Advocated for increased federal funding for digestive diesease research and increased funding for the NIH and NIDDK. Advocate for language in the Labor-HHS Education Appropriations bill on funding recommendations in the final report of the National Commission on Digestive Diseases. Also lobbied in support of an Institute of Medicine study to examine the plight of the MD/PhD investigator and issues involved with recruitment and retention of physician-scientists.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
Lobbied in support of H.R. 1738, the Colorectal Cancer Early Detection, Prevention and Treatment Act, to provide grants to states to develop screening programs for the at-risk, uninsured and underinsured population. Also lobbied in support of access to specialty medicine in the context of health care reform.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Lobbied for Medicare payment reform for physicians and against using budget neutrality to increase payments to primary care. Also, raised concerns regarding the patient-centered medical home and its impact on access to specialty care.
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2008
In Q3, AMERICAN GASTROENTEROLOGICAL ASSN had in-house lobbyists. The report was filed on Oct. 16, 2008.
Original Filing: 300095323.xml
Lobbying Issues
Advocate for reforming the Medicare physician payment system and preventing a 10.6 percent cut in physician payments. Lobbied in support of H.R. 6331, the Medicare Improvement for Patients and Providers Act (H.R. 6331).
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Advocate increased federal funding for digestive disease research and increased funding for NIH, NIDDK, and VA research programs. Advocate for language in the Labor-HHS-Education Appropriations bill on funding recommendations in the final report of the National Commission on Digestive Diseases. Also lobbied in support of an Insitute of Medicine study to examine the plight of the MD/PhD investigator and issues involved with recruitment and retention of physician-scientists.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
Lobbied in support of H.R. 1738, the Colorectal Cancer Early Detection, Prevention and Treatment Act, to provide grants to states to develop screening programs for the at-risk, uninsured and underinsured population.
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2008
In Q2, AMERICAN GASTROENTEROLOGICAL ASSN had in-house lobbyists. The report was filed on July 16, 2008.
Original Filing: 300066821.xml
Lobbying Issues
Advocate for reforming the Medicare physician payment formula and preventing a 10.6 percent cut in physician payments. Lobbied in support of clarrifying the current Medicare deductible waiver for colorectal cancer screenings to include removal of polyps and/or lesions.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Advocate increased federal funding for digestive disease research and increased funding for NIH, NIDDK, and VA Research programs. Advocate for language in the Labor-HHS-Education Appropriations bill on funding recommendations in the final report of the National Commission on Digestive Diseases.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Medical/Disease Research/Clinical Labs
1st Quarter, 2008
In Q1, AMERICAN GASTROENTEROLOGICAL ASSN had in-house lobbyists. The report was filed on April 1, 2008.
Original Filing: 300031682.xml
Lobbying Issues
Advocate increased federal funding for digestive disease research and increased funding for NIH, NIDDK and VA Research program.
Meet to discuss details of the final report on the National Commission on Digestive Diseases.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
Lobbied in support of H.R. 1738, the Colorectal Cancer Early Detection, Prevention and Treatment Act, to provide grants to states to develop screening programs for the at-risk, uninsured and underinsured populations.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Lobbied in support of S. 1519 and H.R. 2749, the Medicare Voluntary Physician Reporting Act, that would revamp the current Physician Quality Reporting Program (PQRI) and require Congress to study the pilot before moving to a permanent program.
Agencies Lobbied
U.S. House of Representatives
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate
Searching...